Wuhan General Group, Inc. (the 'Company' and 'Wuhan') announced a strategic reorganization that will better position the company to capitalize on the rapidly changing Medical Marijuana and Psilocybin Mushroom industries, while more closely aligning the business with the company's three primary growth strategies: optimizing the value of the core; increasing health and well-being product lines, and accelerating distribution of new business models.

Additionally, Mr. Luka Marjanovic is joining the Wuhan team as Head of Product Development for the MJ MedTech division In South Africa. This new appointment solidifies Wuhan's core business operations. Mr. Marjanovic is responsible for the development, implementation, enhancement and support of the Dr. AnnaRx(TM) and Medspresso(TM) products, and delivery channels. This includes conceptual stages through research, development, marketing, training, performance tracking and the entire product life cycle in support of Wuhan's strategic goals and objectives. Mr. Marjanovic is taking an integrative approach to build solutions and drive product development.